VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
FTH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
FTHFaeth Therapeutics, Inc.
$9.04$568M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksFTHCash Flow

Faeth Therapeutics, Inc. (FTH) Cash Flow Statement

8Y historyFree accessUpdated daily

Operating cash flow was negative in every quarter, with -$13.0M in 2026Q3 and a 2026Q1 OCF of -$10.7M against a -$170.2M net loss, suggesting the headline loss is largely non-cash while ongoing burn remains persistent.

Income StatementBalance SheetCash FlowRatios

FTH Cash Flow Statement

Annual statement

FTH Cash Flow Statement

Faeth Therapeutics, Inc. (FTH) cash flow statement — 8-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Cash from Operations-43.27M-20.45M-24.67M-32.02M-39.03M-30.26M-17.7M-8.57M-10.31M
Operating CF Margin %---------
Operating CF Growth %-445.83%17.09%22.96%17.94%-28.97%-70.91%-106.57%16.89%-
Net Income-211.36M-21.09M-30.16M-34.1M-48.59M-36.79M-20.1M-16.74M-13.04M
Depreciation & Amortization106K139K1.32M1.35M1.35M685K209K73K44K
Stock-Based Compensation26.2M1.27M3.13M4.45M5.81M5.66M1.49M01.19M
Deferred Taxes0000019K000
Other Non-Cash Items131.97M811K1.52M603K1.4M57K1.09M4.63M349K
Working Capital Changes9.81M-1.59M-489K-4.33M1.01M117K-397K3.47M1.49M
Change in Receivables000000000
Change in Inventory000000000
Change in Payables1.06M233K-445K-2.33M2.02M-1.43M335K2.34M931K
Cash from Investing-137.25M19.77M22.44M38.41M49.95M-143.12M-1.4M-53K-31K
Capital Expenditures-9K-16K-146K-180K-321K-2.03M-1.21M-53K-31K
CapEx % of Revenue---------
Acquisitions40K250K0166K15K318K-197K00
Investments---------
Other Investing6.42M00000000
Cash from Financing184.14M-645K-787K-11.17M-287K163.94M35.45M8.22M750K
Debt Issued (Net)-193K-648K-811K-761K-629K-255K526K8.07M750K
Equity Issued (Net)201.24M6K34K-10.34M342K164.09M37.01M154K0
Dividends Paid000000000
Share Repurchases0-1K0-10.38M00000
Other Financing-16.91M-3K-10K-76K0109K-2.08M00
Net Change in Cash3.62M-1.33M-3.02M-4.78M10.64M-9.44M16.34M-402K-9.59M
Free Cash Flow-43.28M-20.47M-24.82M-32.2M-39.35M-32.28M-18.91M-8.62M-10.34M
FCF Margin %---------
FCF Growth %-93.24%17.52%22.94%18.16%-21.87%-70.72%-119.28%16.63%-
FCF per Share-1.67-16.24-19.76-23.04-25.63-23.30-12.36-5.88-7.05
FCF Conversion (FCF/Net Income)0.20x0.97x0.82x0.94x0.80x0.82x0.88x0.51x0.79x
Interest Paid00000012K00
Taxes Paid000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Persistent operating cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Cash Burn Tracks Losses Imperfectly

Based on reported figures, FTH's operating cash flow was negative in every quarter shown, with the 2026Q1 OCF of -$10.7M against a net loss of -$170.2M suggesting the headline loss is dominated by non-cash charges rather than operating spending.

The ratio of operating cash flow to net income ranges from 0.06 to 1.20 across the series, which means cash losses have roughly tracked reported losses in most quarters. The 2026Q1 divergence, however, is extreme and appears driven by a non-cash charge rather than cash consumption. Investors should monitor whether that charge reflects an impairment or other accounting item, since the reported figures do not disclose its nature.

Free Cash Flow Deeply Negative Throughout

As reported in the financial statements, FTH's free cash flow has remained negative across all ten quarters, reaching -$15.7M in 2026Q2 and -$13.0M in 2026Q3, with no quarter showing a sustained move toward breakeven.

Free cash flow margins are not meaningful given the near-absence of reported revenue, so the analysis rests on absolute burn. Recent quarters show burn in the $10M to $16M range, which is higher than the $4M to $7M quarterly burn seen in 2024 and 2025. This increase may suggest rising operating commitments, though the reported figures alone do not establish the cause.

Capital Deployed Toward Acquisitions, Not Returns

According to reported cash flow data, FTH paid no dividends or buybacks across the period, while net acquisition outflows of $6.5M in 2026Q1 and $6.5M in 2026Q3 appear to be the only significant discretionary deployment visible.

The absence of shareholder distributions is expected for a pre-revenue biotech, but the acquisition outflows are notable against a company burning cash from operations. Whether these deals are strategic or reflect a pipeline-acquisition model cannot be determined from the supplied figures. Investors should monitor how these outlays are funded given ongoing operating burn.

Stock Compensation Masks Cash Cost Base

Based on reported stock-based compensation, SBC rose from $0.3M in 2025 to $12.9M in 2026Q1, which may indicate that a meaningful share of operating cost is settled in equity rather than cash and could flatter the apparent cash burn.

Adding back SBC would reduce the gap between reported losses and cash losses in several quarters, so the lower cash burn partly reflects non-cash compensation. This does not reduce economic cost, since equity issuance dilutes existing holders. The reported figures do not show the share count trajectory, so the dilution effect warrants further investigation.

FTH — Frequently Asked Questions

Quick answers to the most common questions about buying FTH stock.

How much cash does Faeth Therapeutics, Inc. (FTH) generate from operations?

Faeth Therapeutics, Inc. (FTH) generated $-20.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Faeth Therapeutics, Inc.'s free cash flow?

Faeth Therapeutics, Inc. (FTH) reported negative free cash flow of $20.5M in 2025, indicating capital requirements exceeded cash from operations.

What is Faeth Therapeutics, Inc.'s capital expenditure (CapEx)?

Faeth Therapeutics, Inc. (FTH) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Faeth Therapeutics, Inc. distribute cash to shareholders?

In 2025, Faeth Therapeutics, Inc. (FTH) spent $0.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.